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Intermolecular Displacement of S-Bound L-Methionine on Platinum(1i) by Guanosine 
5’-Monophosphate: Implications for the Mechanism of Action of Anticancer Drugs 
Kevin J. Barnham, Milos 1. Djuran, Piedad del Socorro Murdoch and Peter J. Sadler* 
Department of Chemistry, Birkbeck College, University of London, Gordon House and Christopher lngold 
Laboratories, 29 Gordon Square, London, UK WClH OPP 
NMR investigations of the kinetics and thermodynamics of the competitive binding of L-methionine (Met), 
L-histidine (His), and 5’-monophosphates of guanosine (5‘-GMP), adenosine (5’-AMP), thymidine (5’-TMP) and cytidine 
(5’-CMP) to [Pt(dien)CI]+ (dien = 1,5-diamino-3-azapentane) in aqueous solution show that 5’-GMP selectively displaces 
S-bound Met, a finding which has implications for DNA platination by anticancer drugs in vivo. 
DNA platination is thought to be a key event in the 
mechanism of action of platinum anticancer drugs, and there is 
much current interest in the mechanism of this reaction, 
especially in the formation of Pt-G (guanine) adducts.1 The 
amino acid I>-methionine (Met) is a thioether which plays an 
important role in the metabolism of all cells. Platinum(i1) has a 
very high affinity for sulfur ligands and the bis-chelate- 
[Pt(Met - H-S,N)2] has been isolated from the urine of 
patients treated with the anticancer drug cisplatin {cis- 
[PtC12(NH3)2]}.* This complex, which is a mixture of dia- 
stereoisomers of the cis and trans isomers,3 appears to be a 
stable end-product of cisplatin metabolism and is unreactive 
towards nucleobases at neutral pH.4 However we founds that 
cisplatin reacts with guanosine 5‘-monophosphate (5’-GMP) 
even in the presence of Met, and in order to understand the 
course of the latter reaction, we investigated similar reactions 
Table 1 Kinetic data for reactions of [Pt(dien)Cl]+ and [Pt(dien)(Met- 
S)I2+ with 5’-GMP, where k2 is the second-order rate constant 
Complex Reactant pH*, TtK 104 k21dm3mol-l s-l 
[Pt(dien)CI]+ 1 Metla 3.9,300 140 
GSMeh 5.0.295 330 
S’-GMPh 5.0.29s 0.62~ 
7.0,310 1.66 
7.0.318 3.57 
[Pt(dien)(Met-S)]Z+ 2 5’-GMPu 7.0,298 0.51 
0 40 200 400 600 800 
t l h  
Fig. 1 Time-course of the reaction between [Pt(dien)Cl]+ 1. Met and 
5’-GMP (1 :2:2 mol ratio). Initially there is rapid formation of 
[Pt(dien)(Met-S)12+ 2 followed by displacement of Met by 5’-GMP. In 
the later stages the formation of [Pt(dien)(S’-GMP-W)] 3 is almost 
complete 
of [Pt(dien)Cl]+ 1. Complex 1 has the advantage that the 
chelated dien ligand does not readily behave as a leaving 
group in the presence of sulfur ligands, unlike the ammines on 
cisplatin. We show here that intermolecular displacement of 
S-bound L-methionine by ”-bound 5’-GMP readily occurs, 
and is selective in comparison with the N ligands of other 
DNA bases or L-histidine (His). These findings, together with 
the recent report of intramolecular displacement of a Pt- 
bound thioether by a guanine nucleobase,6 suggest that novel 
routes to DNA platination by platinum anticancer drugs may 
exist in vivo. 
First we studied the competitive reaction of l 7 t  (10 
mmol dm-3) with Met (20 mmol dm-3) and 5’-GMP (20 
mol dm-3) in DzO pH* 7.2.t: In the initial stages of the 
reaction (<40 h), 1H NMR (JEOL GX270) peaks for free Met 
[6 2.136 (C&H3) and 3.869 (CaH)] decreased in intensity, new 
peaks characteristic of [Pt(dien)(Met-S)]2+ 2 appeared in the 
spectrum [6 2.547 (C€H3) and 3.940 (OH)],§ whereas little of 
the 5’-GMP reacted, Fig. 1. In the later stages, the peaks for 
bound Met and free 5’-GMP (6 8.202 for H*) decreased in 
intensity, whereas those for free Met increased in intensity, as 
did those assignable to bound 5’-GMP in [Pt(dien)(S’-GMP- 
W)] 3 (6 8.856 for H*), Fig. 1. In a similar competition 
reaction between Met and adenosine 5’-monophosphate 
(5’-AMP) (pH* 6.3), nearly all the Met reacted with 1 within 
6 h, but only ca. 2.5% of the 5’-AMP had reacted after 30 d at 
ambient temperature. 
In separate experiments we confirmed that the reaction of 1 
with Met alone is relatively fast, and that complex 3 can be 
formed from complex 2 by direct displacement of coordinated 
Met by 5’-GMP. The rate of reaction of Met with 1 (half-life 
2.0 h at 300 K; second-order rate constant k2, Table 1) is 
similar to that reported previously for S-methylglutathione 
(GSMe).7 The direct reaction of the Met adduct 2 with 5’ -  
GMP was studied at 310 K in 50 mmol dm-3 phosphate buffer, 
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linear giving a rate constant of 1.66 x dm3 mol-1 s-1 
(half-life of 167 h). The reaction was also followed at 298 and 
318 K, and an Eyring plot yielded values of AH* of 73.8 
kJ mol-l and A S  of -79.7 J K-l mol-l. These values are 
typical of those reported previously for substitution reactions 
of square-planar platinum(1i) complexes which occur via an 
associative mechanism (five-coordinate transition state) .9 
Reactions of 2 with nucleobases were remarkably selective 
for guanine. In a competitive experiment between 2 (10 
mmol dm-3, 50 mmol dm-3 phosphate buffer, pH* 7.0) 5'- 
GMP, 5'-AMP, 5'-TMP (thymine 5'-monophosphate) and 5 ' -  
CMP (cytosine 5'-monophosphate) (10 mmol dm-3 each), 7% 
of the 5'-GMP had reacted by displacing Met after 12.6 h, but 
none of the other bases had reacted. 
Notable also was the inability of the imidazole N of His to 
displace S-bound Met: no reaction between 2 (10 mol dm-3, 
SO mmol dm-3 phosphate buffer, pH* 7) and 1 mole equiv. of 
His was observed even after 3 d. 
Comparisons between complexes of Pt" and Pd" are of 
interest since Pd" analogues of Pt" antitumour agents are 
usually much less active. For equimolar mixtures of 
[Pd(dien)Cl]+ 1, Met and 5'-GMP, only GMP adducts were 
detected in the NMR spectrum, whereas with Met and 5'- 
AMP, both S-bound Met together with peaks assignable to 
both N*- and N7-bound 5'-AMP were seen. These data are 
consistent with the more rapid substitution reactions of Pd" 
compared to Pt" (often > lo4 times faster), and again with the 
stronger nucleophilicity of guanine compared to adenine. In 
the case of Pd", initial [Pd(dien)(Met)]2+ may convert rapidly 
to [Pd(dien)(s'-GMP-W)], although the reaction with GMP 
may also occur rapidly via aqua species. Palladium(I1) binding 
to N7 has been established by X-ray crystallography of 
[Pd(dien)(guano~ine)](CI04)~ ,lo and Pd" is known to bind 
strongly to both N7 and N1 of AMP." 
These findings have implications for the mechanism of 
action of platinum anticancer drugs. Sulfur ligands are 
generally thought to have a much higher affinity for Pt" than 
nitrogen ligands and to diminish the antitumour activity of 
platinum complexes.12 Indeed sulfur nucleophiles have been 
used as rescue agents to remove excess Pt from the body.13 
The present work and that on intramolecular displacement,6 
which was reported whilst this work was being written up, 
suggest that the binding of thioether sulfur to Pt" is reversible 
and could provide a novel mechanism for DNA platination. 
The displacement of S-bound Met by N7-bound GMP appears 
to be about an order of magnitude slower than the intramole- 
cular isomerization of [Pt(dien)(guanosylhomocysteine-S)] 
reported by van Boom and Reedijk,6 although detailed 
kinetics were not determined for the latter reaction and so a 
proper comparison of rates is not possible. 
Platinum transfer reactions to DNA bases via Met interme- 
diates could have biological significance in cells with high 
concentrations of CI- ions in their nuclei (e .g .  150 mmol dm-3 
in liver cells14) for which the accepted pathway of DNA 
platination via aqua intermediates is likely to be quenched. 
The GMP-Met displacement reactions are slow, but it is 
notable that a very slowly excreted pool of Pt exists in vivo 
after administration of cisplatin (which has a half-life of 
several days).15 In small cellular compartments such as the 
nucleus, the concentrations of the reactants may be effectively 
raised, so increasing the rates of the second-order substitution 
reactions. Also displacement reactions may be facilitated if 
the methionine adduct is formed not simply by Met itself, but 
by an accessible Met residue on a DNA-binding protein. Our 
finding of selective transfer to G as opposed to other DNA 
bases, or to His which is a common residue in proteins, is 
notable since G bases are known to be major targets for Pt 
attack on DNA.16 It will be interesting to investigate the 
effects which Pt-bound Met and methionine-containing pep- 
tides and proteins have on the DNA sequence specificity for G 
attack. Since monodentate S-bound Met has free amino and 
carboxylate groups, rapid transport mechanisms could exist 
for such Pt complexes through cellular compartments via 
amino acid receptors in membranes. Although thiols such as 
glutathione are also abundant S-containing ligands in cells, it is 
notable that thioethers react faster with [Pt(dien)Cl]+ than 
thiols.7J7 Reactions between cisplatin and 5'-GMP in the 
presence of Met are complicated by the loss of ammine 
ligands, but it appears18 that displacement of S-bound Met can 
occur in this case also and therefore may be a general reaction 
available to platinum anticancer complexes. 
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Footnotes 
t The compounds [Pt(dien)Cl]Cl 1 and [Pt(dien)(N03)JN03 were 
prepared as previously described.' [Pt(dien)(Met-S)]*+ 2 was pre- 
pared by mixing pH 2 solutions (adjusted with 1 mol dm-3 HN03) of 
[Pt(dien)(N03)JN03 (2 cm3,50 mmol dm-3) and Met (2 cm3,50 mmol 
dm-3). The reaction was carried out at low pH to avoid coordination 
of the amino group. Complete formation of the product was checked 
by 1I-I NMR spectroscopy and any slight excess of one component was 
corrected if necessary by addition of the other component. The 
solution was lyophilized and the solid complex was stored at -20 "C 
and used as required. 
# pH* is the pH meter reading in D 2 0  solution. 
§ The single set of peaks is indicative of rapid inversion at the chiral S 
centre on the 1H NMR time-scale consistent with monodentate 
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